BioCryst Pharmaceuticals Files 8-K

TL;DR

BioCryst filed an 8-K on 9/30/24 with financial updates.

AI Summary

BioCryst Pharmaceuticals, Inc. filed an 8-K on September 30, 2024, reporting on various events. The filing includes financial statements and exhibits, indicating ongoing business operations and regulatory disclosures. No specific material events like acquisitions or significant financial changes were detailed in the provided excerpt.

Why It Matters

This 8-K filing provides an update on BioCryst Pharmaceuticals' corporate activities and financial reporting, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not appear to contain any immediately alarming information.

Key Players & Entities

• BioCryst Pharmaceuticals, Inc. (company) — Registrant
• September 30, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Durham, North Carolina (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $69 million — ("HHS") has awarded the Company up to a $69 million contract (the "HHS Contract") for the p
• $13.9 m — executed the first ordering period for $13.9 million, and the Company plans to supply
• $69 Million — titled "U.S. Government Awards BioCryst $69 Million RAPIVAB (peramivir injection) Contract

Filing Documents

• f8k_093024.htm (8-K) — 18KB
• exh_991.htm (EX-99.1) — 6KB
• 0001171843-24-005393.txt ( ) — 222KB
• gnw-20190101.xsd (EX-101.SCH) — 3KB
• gnw-20190101_def.xml (EX-101.DEF) — 25KB
• gnw-20190101_lab.xml (EX-101.LAB) — 33KB
• gnw-20190101_pre.xml (EX-101.PRE) — 22KB
• f8k_093024_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 30, 2024, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing the events described in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Other Events

Item 8.01. Other Events. On September 30, 2024, the Company announced that the U.S. Department of Health and Human Services ("HHS") has awarded the Company up to a $69 million contract (the "HHS Contract") for the procurement of up to 95,625 doses over a five-year period of RAPIVAB (peramivir injection) for the treatment of influenza. The HHS Contract, awarded by the HHS Office of the Administration for Strategic Preparedness and Response ("ASPR"), will supply the Center for the Strategic National Stockpile, the nation's largest supply of life-saving pharmaceuticals and medical supplies for use in a public health emergency. The HHS Contract is structured with a 12-month base ordering period and four optional 12-month ordering periods, which the government can exercise on an annual basis. ASPR has executed the first ordering period for $13.9 million, and the Company plans to supply 19,125 doses to fulfill this option between now and September 29, 2025.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements, including statements regarding the Company's plans and expectations for RAPIVAB. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the HHS may purchase smaller quantities of RAPIVAB than currently anticipated, or none at all; the Company relies on third-party manufacturers to manufacture RAPIVAB in a timely manner and in accordance with applicable governmental regulations, and any failure of such third-party manufacturers to perform their obligations could impact the Company's ability to supply RAPIVAB pursuant to the HHS Contract; and government contracts contain certain terms and conditions, including termination provisions, that subject the Company to additional risks. Please refer to the documents the Company files periodically with the Securities and Exchange Commission, specifically the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause the actual results to differ materially from those contained in the Company's forward-looking statements.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated September 30, 2024 entitled "U.S. Government Awards BioCryst $69 Million RAPIVAB (peramivir injection) Contract for Strategic National Stockpile" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioCryst Pharmaceuticals, Inc. Date: September 30, 2024 By: /s/ Alane Barnes Alane Barnes Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR